Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.


29 Sep 2019


Poster Display session 2


Tumour Site

Neuroendocrine Neoplasms


Rahul Ladwa


Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256


R. Ladwa1, D. Pattison2, J. Smith2, S. Goodman2, M. Burge3, S. Rose4, N. Dowson4, D.K. Wyld3

Author affiliations

  • 1 Dept Medical Oncology, Princess Alexandra Hospital, 4102 - Brisbane/AU
  • 2 Nuclear Medicine & Specialised Pet Services, Royal Brisbane & Women's Hospital, Brisbane/AU
  • 3 Dept Medical Oncology, Royal Brisbane & Women's Hospital, Brisbane/AU
  • 4 The Australian E-health Research Centre, CSIRO Health and Biosecurity, Brisbane/AU


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3253


Peptide receptor radionuclide therapy (PRRT) with 177Lutetium (177Lu) -DOTATATE is effective treatment for neuroendocrine tumors (NETs). Dosimetry assessment can be used to maximize the tumour dose, while keeping the dose delivered to critical organs to acceptable levels. The association between tumour absorbed dosimetry (TAD) and progression-free (PFS) and overall survival (OS) is not well understood.


Single institution retrospective analysis of patients with metastatic NET whom underwent up to 4 cycles of 7.45GBq 177Lu octreotate PRRT. Intra-therapeutic tumour dosimetry was performed with non-gated single photon emission computed tomography (SPECT) to quantify activity at 5 time points after administration of 177 Lu during cycle 1. TAD per injected activity (A0) and estimated total TAD (multiplied by total administered activity of 177Lu) was correlated with OS and PFS using the Kaplan–Meier method and Cox proportional-hazards model.


79 patients were included, primary site: gastroenteric (48%), pancreatic (39%), bronchial (9%), other (4%), ECOG Performance status (PS) 0/1 (94%), Grade: G1 (47%), G2 (42%), G3 (11%), Ki-67≤20% (89%), concurrent chemotherapy use (29%). Mean TAD/A0 was 9(7-11) Gy/GBq. Progressive disease (54%) and death (29%) was seen. Median follow-up of 35 months. Median PFS was 32 [26-38] months. PFS was shorter with increasing ECOG PS (P = 0.02), tumour grade (P < 0.01), Ki-67 (P = 0.01), concurrent chemo-radionuclide therapy (P = 0.02) and reduced TAD (P = 0.036) but not primary site of origin (P = 0.66). A higher TAD led to an improved median PFS in pancreatic (P < 0.01) versus gastroenteric (P = 0.56) NETs. In a multivariate model incorporating ECOG PS, Ki-67 and chemotherapy use, total TAD remained significantly associated with PFS. The mean OS was 40 [36-44] months. OS was shorter with increasing tumour grade (P = 0.05), Ki-67 (P = 0.036) and reduced TAD (P = 0.039).


TAD was independently associated with OS and PFS validating dosimetry assessment in NET patients undergoing PRRT. Prospective refinement of the association on larger, more homogenous cohorts of NET patients is needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.